PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern ChinaASIAN JOURNAL OF ANDROLOGYIF2.72018-01-018OAAI
未登录.png){kind=icon}
未登录
